HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
1. A pharmaceutical composition comprising a vestigial-like 1 (VGLL1) peptide of 35 amino acids in length or less comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a pharmaceutical carrier, wherein the peptide is capable of inducing cytotoxic T lymphocytes (CTLs) and the pharmaceutical carrier is not only water.
2. The composition of claim 1 , wherein the peptide comprises an amino acid sequence of SEQ ID NO: 1.
3. The composition of claim 1 , wherein the peptide binds to a human class I HLA protein.
4. The composition of claim 3 , wherein the human class I HLA protein is from the HLA-A1 family, the HLA-A29 family, the HLA-A30 family, the HLA-B18 family, or the HLA-B44 family.
5. The composition of claim 3 , wherein the human class I HLA protein is HLA-A*0101, HLA-A*0102, HLA-A*0103, HLA-A*2902, HLA-A*3002, HLA-B*1801, or HLA-B*4403.
6. The composition of claim 1 , wherein the peptide is 30 amino acids in length or less.
7. A method of promoting an immune response in a subject, comprising administering an effective amount of a vestigial-like 1 (VGLL1) peptide of 35 amino acids in length or less comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein the peptide induces VGLL1-specific T cells in the subject.
8. The method of claim 7 , wherein the subject is diagnosed with cancer.
9. The method of claim 8 , wherein the cancer is pancreatic, ovarian, gastric, or breast cancer.
10. The method of claim 7 , further comprising administering at least a second anti-cancer therapy.
11. The method of claim 10 , wherein the second anti-cancer therapy is selected from the group consisting of a chemotherapy, a radiotherapy, an immunotherapy, or a surgery.
12. The method of claim 11 , wherein the immunotherapy is an immune checkpoint inhibitor.
13. The method of claim 12 , wherein the immune checkpoint inhibitor is an anti-PD1 monoclonal antibody.
14. The composition of claim 1 , wherein the peptide is comprised in a liposome, lipid-containing nanoparticle, or in a lipid-based carrier.
15. The composition of claim 1 , wherein the pharmaceutical composition is formulated for injection or inhalation as a nasal spray.
16. The composition of claim 1 , wherein the pharmaceutical carrier is a non-aqueous solvent, oil, dispersion media, coating, surfactant, antioxidant, preservative, isotonic agent, absorption delaying agent, salt, drug, drug stabilizer, gel, binder, excipient, disintegration agent, and/or lubricant.
17. The composition of claim 1 , wherein the pharmaceutical composition further comprises an adjuvant.